Vertex Pharmaceuticals Incorporated
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.
- Conditions
- First Posted Date
- 2006-10-18
- Last Posted Date
- 2009-09-24
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 36
- Registration Number
- NCT00389298
- Locations
- 🇨🇦
Foothills Medical Centre, Calgary, Alberta, Canada
🇨🇦Liver and Intestinal Research Centre, Vancouver, British Columbia, Canada
🇨🇦Ottawa Hospital; General Campus, Ottawa, Ontario, Canada
Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2006-09-06
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 334
- Registration Number
- NCT00372385
- Locations
- 🇬🇧
Call for Information, Call for Information, United Kingdom
🇩🇪Call For Information, Call For Information, Germany
Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2006-06-13
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 263
- Registration Number
- NCT00336479
- Locations
- 🇺🇸
Fox Chase/ Temple Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸South Denver Gastroenterology, Englewood, Colorado, United States
🇺🇸Call for Information, New York, New York, United States
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2011-08-04
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 72
- Registration Number
- NCT00273936
- Locations
- 🇺🇸
George Washington University, Washington, District of Columbia, United States
🇺🇸Arizona Clinical Research Center, Tucson, Arizona, United States
🇺🇸Ohio State University, James Cancer Hospital Comprehensive Cancer Center, Columbus, Ohio, United States
Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C
- Conditions
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 12
- Registration Number
- NCT00262483
- Locations
- 🇵🇷
Call for information, Santurce, Puerto Rico
VX-950 and Peginterferon for Hepatitis C
- Conditions
- First Posted Date
- 2005-11-09
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 20
- Registration Number
- NCT00251199
- Locations
- 🇳🇱
Call for information, Amsterdam, Netherlands
Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-12-07
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 300
- Registration Number
- NCT00205478
- Locations
- 🇺🇦
Dniepropetrovsk State Medical Academy, Dniepropetrovsk, Ukraine
🇺🇦Zaporizhya Medical Institute, Zaporizhya, Ukraine
🇧🇬MBAL "Stara Zagora" EAD, Stara Zagora, Bulgaria
Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-12-05
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 64
- Registration Number
- NCT00205465
Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C
- Conditions
- First Posted Date
- 2004-07-28
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 315
- Registration Number
- NCT00088504
- Locations
- 🇺🇸
David N. Schwartz, M.D., Attleboro, Massachusetts, United States
🇺🇸Lawrence D. Wruble, M.D., Memphis, Tennessee, United States
🇺🇸Lawton Shick, M.D., Worcester, Massachusetts, United States
VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 36
- Registration Number
- NCT00003847
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Duke Comprehensive Cancer Center, Durham, North Carolina, United States